Literature DB >> 26193348

Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection.

Maria Paula Henao1, Meenakshi Bewtra, Mark T Osterman, Faten N Aberra, Frank I Scott, Gary R Lichtenstein, Jennifer Kraschnewski, James D Lewis.   

Abstract

BACKGROUND: The Crohn's Disease Activity Index (CDAI) and Mayo score for ulcerative colitis (UC) require symptom recall and/or use of a symptom diary. We examined patients' abilities to recall their symptoms and the day-to-day variability of symptoms.
METHODS: Patients with UC or CD completed a questionnaire including items from the short CDAI (sCDAI) and the 6-point Mayo score. Patients were randomized to receive a follow-up questionnaire testing recall of the bowel symptom items between 1 and 7 days later. In a second study, patients completed a 7-day electronic diary recording their symptoms. sCDAI and 6-point Mayo scores were computed. Analyses estimated daily variability in the indices and misclassification rates when using fewer than 7 days of data.
RESULTS: 100%, 82%, and 90% of CD participants recalled the same disease activity status (i.e., active versus remission) as reported on the initial survey when the follow-up questionnaire was administered 1 to 2, 3 to 5, and 6 to 8 days later, respectively. Compared with using 7 days of data, when using only day 7 data, 3.7% of patients with CD were misclassified as active or inactive. Disease activity was misclassified in 2.8%, 4.9%, and 3.3% of patients by using the last 2, 3, or 4 days, respectively. Results were similar for patients with UC.
CONCLUSIONS: Patients with CD and UC demonstrated good recall of bowel symptoms for up to 8 days. Additionally, bowel symptoms have relatively little variability within a 7-day period allowing for accurate computation of the sCDAI and 6-point Mayo score using 1 to 3 days of data.

Entities:  

Mesh:

Year:  2015        PMID: 26193348      PMCID: PMC4567473          DOI: 10.1097/MIB.0000000000000496

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  19 in total

1.  Influence of recall period on estimates of diarrhoea morbidity in infants in rural Tamilnadu.

Authors:  R Ramakrishnan; T Venkatarao; P K Koya; P Kamaraj
Journal:  Indian J Public Health       Date:  1999 Oct-Dec

Review 2.  The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease.

Authors:  E M Yoshida
Journal:  Can J Gastroenterol       Date:  1999 Jan-Feb       Impact factor: 3.522

3.  Patient non-compliance with paper diaries.

Authors:  Arthur A Stone; Saul Shiffman; Joseph E Schwartz; Joan E Broderick; Michael R Hufford
Journal:  BMJ       Date:  2002-05-18

4.  Reporting errors in one-week diarrhoea recall surveys: experience from a prospective study in rural Bangladesh.

Authors:  N Alam; F J Henry; M M Rahaman
Journal:  Int J Epidemiol       Date:  1989-09       Impact factor: 7.196

5.  Variability of momentary pain predicts recall of weekly pain: a consequence of the peak (or salience) memory heuristic.

Authors:  Arthur A Stone; Joseph E Schwartz; Joan E Broderick; Saul S Shiffman
Journal:  Pers Soc Psychol Bull       Date:  2005-10

6.  Daily morbidity records: recall and reliability.

Authors:  P Byass; P W Hanlon
Journal:  Int J Epidemiol       Date:  1994-08       Impact factor: 7.196

7.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  Quality indicators for inflammatory bowel disease: development of process and outcome measures.

Authors:  Gil Y Melmed; Corey Allan Siegel; Brennan M Spiegel; John I Allen; Robert Cima; Jean-Frederic Colombel; Themistocles Dassopoulos; Lee A Denson; Sharon Dudley-Brown; Andrew Garb; Stephen B Hanauer; Michael D Kappelman; James D Lewis; Isabelle Lynch; Amy Moynihan; David T Rubin; R Balfour Sartor; Ronald M Schwartz; Douglas C Wolf; Thomas A Ullman
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

9.  The accuracy of pain and fatigue items across different reporting periods.

Authors:  Joan E Broderick; Joseph E Schwartz; Gregory Vikingstad; Michelle Pribbernow; Steven Grossman; Arthur A Stone
Journal:  Pain       Date:  2008-05-01       Impact factor: 6.961

10.  Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease.

Authors:  Leighann Litcher-Kelly; Quinn Kellerman; Stephen B Hanauer; Arthur A Stone
Journal:  Ann Behav Med       Date:  2007-04
View more
  4 in total

1.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

2.  Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.

Authors:  Emily E Vivio; Navya Kanuri; Joanna J Gilbertsen; Kelly Monroe; Neelendu Dey; Chien-Huan Chen; Alexandra M Gutierrez; Matthew A Ciorba
Journal:  J Crohns Colitis       Date:  2015-12-17       Impact factor: 9.071

3.  Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis.

Authors:  Xiao-Fei Zhang; Peng Li; Xue-Li Ding; Hao Chen; Shao-Jun Wang; Sheng-Bo Jin; Jing Guo; Zi-Bin Tian
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-07-15

4.  MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease.

Authors:  Jing Feng; Qi Feng; Yueying Chen; Tian Yang; Saiming Cheng; Yuqi Qiao; Jun Shen
Journal:  Front Nutr       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.